JP2006516280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516280A5 JP2006516280A5 JP2006500735A JP2006500735A JP2006516280A5 JP 2006516280 A5 JP2006516280 A5 JP 2006516280A5 JP 2006500735 A JP2006500735 A JP 2006500735A JP 2006500735 A JP2006500735 A JP 2006500735A JP 2006516280 A5 JP2006516280 A5 JP 2006516280A5
- Authority
- JP
- Japan
- Prior art keywords
- sphingolipid
- food
- agent
- formula
- unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 17
- 150000003408 sphingolipids Chemical class 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 5
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 150000001323 aldoses Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 claims 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims 1
- 229940033329 phytosphingosine Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1022442A NL1022442C2 (nl) | 2003-01-20 | 2003-01-20 | Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen. |
| EP03078141 | 2003-10-06 | ||
| PCT/NL2004/000048 WO2004064820A2 (en) | 2003-01-20 | 2004-01-20 | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516280A JP2006516280A (ja) | 2006-06-29 |
| JP2006516280A5 true JP2006516280A5 (enExample) | 2007-03-01 |
Family
ID=32773655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500735A Pending JP2006516280A (ja) | 2003-01-20 | 2004-01-20 | 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7968529B2 (enExample) |
| EP (1) | EP1585508B1 (enExample) |
| JP (1) | JP2006516280A (enExample) |
| AT (1) | ATE427106T1 (enExample) |
| DE (1) | DE602004020316D1 (enExample) |
| ES (1) | ES2325260T3 (enExample) |
| WO (1) | WO2004064820A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
| DE602004020316D1 (de) | 2003-01-20 | 2009-05-14 | Tno | Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. |
| US20050196461A1 (en) * | 2004-01-14 | 2005-09-08 | Udell Ronald G. | Ceramide formulations suitable for oral administration |
| AU2005220692A1 (en) * | 2004-03-16 | 2005-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
| JP4359204B2 (ja) * | 2004-03-19 | 2009-11-04 | 花王株式会社 | 皮膚保湿用食品 |
| EP1618876A1 (en) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for prevention and treatment of atherosclerosis |
| US7648714B2 (en) | 2004-08-05 | 2010-01-19 | Kao Corporation | Food for skin moisture retention |
| DE102004052697A1 (de) * | 2004-10-29 | 2006-05-04 | Haehner, Thomas, Dr. | Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation |
| EP1830829B1 (en) | 2004-11-30 | 2012-01-04 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Sphingolipids in treatment and prevention of hepatic steatosis |
| JP4040069B2 (ja) * | 2005-08-09 | 2008-01-30 | 株式会社ミツカングループ本社 | 脳機能改善用組成物 |
| JP4040070B2 (ja) * | 2005-08-22 | 2008-01-30 | 株式会社ミツカングループ本社 | 筋肉損傷抑制組成物 |
| JP2008013579A (ja) * | 2005-08-22 | 2008-01-24 | Mitsukan Group Honsha:Kk | 筋肉損傷抑制組成物 |
| US20100048928A1 (en) * | 2005-09-22 | 2010-02-25 | Snow Brand Milk Products Co., Ltd | Medicine, Food and Drink or Feed Containing Sphingomyelin |
| EP1815745A1 (en) | 2006-02-03 | 2007-08-08 | Friesland Brands B.V. | Cholesterol-lowering dairy products and methods for their preparation |
| ES2431142T3 (es) * | 2006-04-07 | 2013-11-25 | Megmilk Snow Brand Co., Ltd. | Inhibidor de acumulación de grasa para el tratamiento de síndrome metabólico |
| TWI589228B (zh) | 2009-04-23 | 2017-07-01 | S A Corman | 降低膽固醇含量之奶產品 |
| WO2010131718A1 (ja) * | 2009-05-13 | 2010-11-18 | 丸大食品株式会社 | 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤 |
| WO2013119857A1 (en) | 2012-02-07 | 2013-08-15 | The Regents Of The University Of California | Glycosphingolipids for use in modulating immune responses |
| EP2906576B1 (en) | 2012-10-12 | 2019-09-11 | The Brigham and Women's Hospital, Inc. | Glycosphingolipids and methods of use thereof |
| JP2016013083A (ja) * | 2014-07-01 | 2016-01-28 | 花王株式会社 | 麺つゆ |
| JP6232008B2 (ja) * | 2015-03-19 | 2017-11-15 | 国立大学法人北海道大学 | 酸化抑制剤及びこれを用いた油脂含有飲食品 |
| US20170044516A1 (en) | 2015-08-11 | 2017-02-16 | Industrial Technology Research Institute | Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492259A1 (fr) | 1980-10-21 | 1982-04-23 | Idinvex Sa | Formulation d'heparine |
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| JPS6344842A (ja) | 1986-08-12 | 1988-02-25 | Kao Corp | 油中水中油型乳化油脂組成物 |
| US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
| IT1235162B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisosfingolipidi |
| US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
| US5231090A (en) * | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| BR9106744A (pt) | 1990-08-13 | 1993-07-20 | Univ Duke | Processo para induzir diferenciacao celular,preparacao farmaceutica,composicao e uso de um composto |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5232837A (en) * | 1991-08-05 | 1993-08-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US5374616A (en) * | 1991-10-18 | 1994-12-20 | Georgetown University | Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor |
| US6190894B1 (en) * | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
| US5478860A (en) * | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
| US5830853A (en) * | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US20020182250A1 (en) * | 1995-09-06 | 2002-12-05 | Goro Hori | Lipid metabolism improving agent |
| AU7374396A (en) | 1995-09-29 | 1997-04-17 | Georgetown University | Use of sphingosylphosphorylcholine as a wound-healing agent |
| DE19602108A1 (de) | 1996-01-22 | 1997-07-24 | Beiersdorf Ag | Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen |
| EP0888458A4 (en) | 1996-02-20 | 2004-05-06 | Sloan Kettering Institutefor C | COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER |
| EP1520583B1 (en) | 1997-04-10 | 2009-01-28 | Kyowa Hakko Kirin Co., Ltd. | NKT cell-activating agents containing alpha-glycosylceramides |
| US6800661B1 (en) * | 1997-04-15 | 2004-10-05 | Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| US5989803A (en) * | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
| EP1053243B1 (en) | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid derivatives and their methods of use |
| JP3581010B2 (ja) | 1998-03-18 | 2004-10-27 | 雪印乳業株式会社 | 脂質の消化吸収機能改善剤 |
| CA2329124A1 (en) | 1998-05-26 | 1999-12-02 | Office Of The Dean Of Research And Graduate Education | Sphingosine kinase, cloning, expression and methods of use |
| CA2362549A1 (en) * | 1999-02-24 | 2000-08-31 | John Hopkins University | Compositions and methods for modulating serum cholesterol |
| US6713057B1 (en) * | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| JP3544493B2 (ja) | 1999-06-10 | 2004-07-21 | 雪印乳業株式会社 | 乳幼児用栄養組成物 |
| KR100341793B1 (ko) | 1999-07-02 | 2002-06-24 | 권 영 근 | 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제 |
| EP1195165A4 (en) * | 1999-07-12 | 2005-08-10 | Ono Pharmaceutical Co | FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS |
| JP2001213858A (ja) | 1999-11-24 | 2001-08-07 | Sagami Chem Res Center | スフィンゴシン誘導体 |
| JP2001158735A (ja) * | 1999-11-30 | 2001-06-12 | Snow Brand Milk Prod Co Ltd | 歯周病の予防及び改善剤 |
| JP2001158736A (ja) | 1999-11-30 | 2001-06-12 | Snow Brand Milk Prod Co Ltd | 骨関節疾患の予防及び改善剤 |
| JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| AU2001255199A1 (en) | 2000-03-28 | 2001-10-08 | The Liposome Company, Inc. | Ceramide derivatives and method of use |
| JP2002068998A (ja) | 2000-08-29 | 2002-03-08 | Meiji Milk Prod Co Ltd | 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物 |
| WO2002034062A1 (en) | 2000-10-27 | 2002-05-02 | Nv Marc Boone | Method for obtaining products enriched in phospho- and sphingolipids |
| AU2002226919A1 (en) * | 2000-11-22 | 2002-06-03 | Kc And Aa, Inc. | Portable cooler for beverage container |
| US6949247B2 (en) * | 2000-12-28 | 2005-09-27 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Stable skin care compositions containing a retinoid and a retinoid booster system |
| FR2820037B1 (fr) | 2001-01-29 | 2005-12-09 | Dermaconcept Jmc | Composition dermatologique a usage veterinaire comprenant une base sphingoide |
| JP2002226394A (ja) | 2001-02-01 | 2002-08-14 | Meiji Milk Prod Co Ltd | 脂質代謝改善組成物 |
| JP4958339B2 (ja) * | 2001-03-21 | 2012-06-20 | 雪印メグミルク株式会社 | 脂質代謝改善剤 |
| US20040241249A1 (en) * | 2001-06-18 | 2004-12-02 | Tina Sampalis | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport |
| DK1417211T3 (da) | 2001-07-27 | 2007-10-08 | Neptune Technologies & Bioress | Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse |
| DE60117900D1 (de) | 2001-09-05 | 2006-05-11 | Charmzone Co | Phytosphingosinderivate mit Antitumorwirkung |
| US20030109044A1 (en) * | 2001-10-16 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Methods of using 279, a human G protein-coupled protein receptor |
| JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
| DE10217555A1 (de) | 2002-04-19 | 2004-02-19 | Degussa Bioactives Deutschland Gmbh | Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix |
| MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| US20060166934A1 (en) | 2002-08-14 | 2006-07-27 | Tae-Yoon Kim | Composition comprising phytosphingosine derivatives for apoptosis induction |
| DE602004020316D1 (de) | 2003-01-20 | 2009-05-14 | Tno | Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. |
| NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
| GB0301395D0 (en) | 2003-01-21 | 2003-02-19 | Univ Aston | Inflammatory disorder treatment |
| US20040171522A1 (en) | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| KR20060015534A (ko) | 2003-04-25 | 2006-02-17 | 더 펜 스테이트 리서치 파운데이션 | 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템 |
-
2004
- 2004-01-20 DE DE602004020316T patent/DE602004020316D1/de not_active Expired - Lifetime
- 2004-01-20 AT AT04703544T patent/ATE427106T1/de not_active IP Right Cessation
- 2004-01-20 ES ES04703544T patent/ES2325260T3/es not_active Expired - Lifetime
- 2004-01-20 WO PCT/NL2004/000048 patent/WO2004064820A2/en not_active Ceased
- 2004-01-20 US US10/542,845 patent/US7968529B2/en not_active Expired - Fee Related
- 2004-01-20 EP EP04703544A patent/EP1585508B1/en not_active Revoked
- 2004-01-20 JP JP2006500735A patent/JP2006516280A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2809318B1 (en) | Ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use | |
| JP2012526094A5 (enExample) | ||
| JP5721631B2 (ja) | 酸性セラミダーゼのリソソーム親和性阻害剤 | |
| JP2007529507A5 (enExample) | ||
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| RU2007114290A (ru) | Способы и композиции для лечения гиперлипидемии | |
| RU2009106934A (ru) | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента | |
| JP2012508249A5 (enExample) | ||
| WO2004064820A3 (en) | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels | |
| ES2759312T3 (es) | Compuestos de aminocarbonilcarbamato | |
| TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
| JP2014505017A5 (enExample) | ||
| WO2008069652A1 (en) | Combinations of a sphingolipid and an hmg-coa reductase inhibitor for treating hypercholesterolemia | |
| JP2011529069A5 (enExample) | ||
| CA2521836A1 (en) | Phosphates of secondary alcohols | |
| WO2010072209A3 (de) | Nahrungsergänzungsmittel auf der basis von pantothensäure | |
| JP2006516278A5 (enExample) | ||
| DE602004016727D1 (de) | Sphingolipiden zur verbesserung der darmflorazusammensetzung | |
| EP2475361A1 (en) | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation | |
| US10624908B2 (en) | Phosphopantetheine compounds alone or in combination with HMG-CoA reductase inhibitors for lowering serum cholesterol and serum triglicerides | |
| CA2616918A1 (en) | Mao-b inhibitors useful for treating obesity | |
| JP2014509305A5 (enExample) | ||
| EP2566473A1 (en) | Dosage regimen of diaryl sulfide derivatives | |
| JP2008546652A5 (enExample) | ||
| EP2262763A2 (en) | Compounds and methods of treating obesity |